Dysimmune polyneuropathies - New diagnostic and therapeutic insights

Schweizer Archiv fur Neurologie und Psychiatrie

Volumn 157, Issue 7, 2006, Pages 307-316

  Renaud, Susanne ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Anti MAG associated neuropathy; CIDP; Dysimmune neuropathies; Rituximab; Vasculitic neuropathy

Indexed keywords

ACYL COENZYME A DESATURASE; ALLOGRAFT INFLAMMATORY FACTOR 1; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN; MYELIN ASSOCIATED GLYCOPROTEIN; PREPROTACHYKININ; PROTEIN ANTIBODY; RHESUS D ANTIBODY; RITUXIMAB;

ARTICLE; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DNA MICROARRAY; DYSIMMUNE POLYNEUROPATHY; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOCOMPETENT CELL; PLASMAPHERESIS; POLYNEUROPATHY; PREVALENCE;

EID: 33750337140     PISSN: 02587661     EISSN: None     Source Type: Journal    
DOI: 10.4414/sanp.2006.01774     Document Type: Article

References (96)

1. Martyn CN, Hughes RA. Epidemiology of peripheral neuropathy. J Neurol Neurosurg Psychiatry 1997;62:310-8.
2. Hartung HP, Willison HJ, Kieseier BC. Acute immunoinflammatory neuropathy: update on Guillain-Barré syndrome. Curr Opin Neurol 2002;15:571-7.
3. Willison HJ. The immunobiology of Guillain-Barré syndromes. J Peripher Nerv Syst 2005;10:94-112.
4. Yuki N, Susuki K, Koga M, Nishimoto Y, Odaka M, Hirata K, et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barré syndrome. Proc Natl Acad Sci U S A 2004;101:11404-9.
5. Ogawa-Goto K, Abe T. Gangliosides and glycosphingolipids of peripheral nervous system myelins - a minireview. Neurochem Res 1998;23:305-10.
6. Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka KV, et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol 1998;44:780-8.
7. Hadden RD, Karch H, Hartung HP, Zielasek J, Weissbrich B, Schubert J, et al. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology 2001;56:758-65.
8. Rees JH, Gregson NA, Hughes RA. Anti-ganglioside GMl antibodies in Guillain-Barré syndrome and their relationship to Campylobacter jejuni infection. Ann Neurol 1995;38:809-16.
9. Jacobs BC, van Doom PA, Schmitz PI, Tio-Gillen AP, Herbrink P, Visser LH, et al. Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome. Ann Neurol 1996;40:181-7.
10. McKhann GM, Cornblath DR, Griffin JW, Ho TW, Li CY, Jiang Z, et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol 1993;33:333-42.
11. Hafer-Macko C, Hsieh ST, Li CY, Ho TW, Sheikh K, Cornblath DR, et al. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol 1996;40:635-44.
12. Ho TW, Mishu B, Li CY, Gao CY, Cornblath DR, Griffin JW, et al. Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and antiglycolipid antibodies. Brain 1995;118:597-605.
13. Menge T, Hemmer B, Nessler S, Wiendl H, Neuhaus O, Hartung HP, et al. Acute disseminated encephalomyelitis: an update. Arch Neurol 2005;62:1673-80.
14. Schwarz S, Mohr A, Knauth M, Wildemann B, Storch-Hagenlocher B. Acute disseminated encephalomyelitis: a follow-up study of 40 adult patients. Neurology 2001;56:1313-8.
15. Kesselring J, Miller DH, Robb SA, Kendall BE, Moseley IF, Kingsley D, et al. Acute disseminated encephalomyelitis. MRI findings and the distinction from multiple sclerosis. Brain 1990;113:291-302.
16. Huber S, Kappos L, Fuhr P, Wetzel S, Steck AJ. Combined acute disseminated encephalomyelitis (ADEM) and acute motor axonal neuropathy (AMAN) after vaccination for hepatitis A and infection with C. jejuni. J Neurol 1999;246:1204-6.
17. Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, Groover RV. Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 1975;50:621-37.
18. Barohn RJ, Kissel JT, Warmolts JR, Mendell JR. Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol 1989;46:878-84.
19. Köller H, Kieseier BC, Jander S, Hartung HP. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 2005;352:1343-56.
20. Köller H, Schroeter M, Kieseier BC, Hartung HP. Chronic inflammatory demyelinating polyneuropathy - update on pathogenesis, diagnostic criteria and therapy. Curr Opin Neurol 2005;18:273-8.
21. Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology 1991;41:617-8.
22. Saperstein DS, Katz JS, Amato AA, Barohn RJ. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve 2001;24:311-24.
23. Berger AR, Bradley WG, Brannagan TH, Busis NA, Cros DP, Dalakas MC, et al. Neuropathy Association, Medical Advisory Committee. Guidelines for the diagnosis and treatment of chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst 2003;8:282-4.
24. Toyka KV, Gold R. The pathogenesis of CIDP: rationale for treatment with immunomodulatory agents. Neurology 2003;60:S2-7.
25. Kieseier BC, Kiefer R, Gold R, Hemmer B, Willison HJ, Hartung HP. Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 2004;30:131-56.
26. Dalakas MC. Mechanism of action of IVIG and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology 2002;59(Suppl 6):13-21.
27. Melendez-Vasquez C, Redford J, Choudhary PP, Gray IA, Maitland P, Gregson NA, et al. Immunological investigation of chronic inflammatory demyelinating polyradiculoneuropathy. J Neuroimmunol 1997;73:124-34.
28. Schmidt B, Toyka KV, Kiefer R, Full J, Hartung HP, Pollard J. Inflammatory infiltrates in sural nerve biopsies in Guillain-Barré syndrome and chronic inflammatory demyelinating neuropathy. Muscle Nerve 1996;19:474-87.
29. Bosboom WM, Van den Berg LH, Mollee I, Sasker LD, Jansen J, Wokke JH, et al. Sural nerve T-cell receptor Vbeta gene utilization in chronic inflammatory demyelinating polyneuropathy and vasculitic neuropathy. Neurology 2001;56:74-81.
30. Winer J, Hughes S, Cooper J, Ben-Smith A, Savage C. Gamma delta T cells infiltrating sensory nerve biopsies from patients with inflammatory neuropathy. J Neurol 2002;249:616-21.
31. Sullivan BA, Nagarajan NA, Kronenberg M. CD1 and MHC II find different means to the same end. Trends Immunol 2005;26:282-8.
32. van Rhijn I, van den Berg LH, Bosboom WM, Otten HG, Logtenberg T. Expression of accessory molecules for T-cell activation in peripheral nerve of patients with CIDP and vasculitic neuropathy. Brain 2000;123:2020-9.
33. Kiefer R, Kieseier BC, Stoll G, Hartung HP. The role of macrophages in immune-mediated damage to the peripheral nervous system. Prog Neurobiol 2001;64:109-27.
34. Sommer C, Koch S, Lammens M, Gabreels-Festen A, Stoll G, Toyka KV. Macrophage clustering as a diagnostic marker in sural nerve biopsies of patients with CIDP. Neurology 2005;65:1924-9.
35. Kieseier BC, Clements JM, Pischel HB, Wells GM, Miller K, Gearing AJ, et al. Matrix metalloproteinases MMP-9 and MMP-7 are expressed in experimental autoimmune neuritis and the Guillain-Barré syndrome. Ann Neurol 1998;43:427-34.
36. Paul R, Lorenzl S, Koedel U, Sporer B, Vogel U, Frosch M, et al. Matrix metalloproteinases contribute to the blood-brain barrier disruption during bacterial meningitis. Ann Neurol 1998;44:592-600.
37. Clements JM, Cossins JA, Wells GM, Corkill DJ, Helfrich K, Wood LM, et al. Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor. J Neuroimmunol 1997;74:85-94.
38. Cossins JA, Clements JM, Ford J, Miller KM, Pigott R, Vos W, et al. Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions. Acta Neuropathol (Berl) 1997;94:590-8.
39. Cuzner ML, Gveric D, Strand C, Loughlin AJ, Paemen L, Opdenakker G, et al. The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J Neuropathol Exp Neurol 1996;55:1194-204.
40. Gijbels K, Masure S, Carton H, Opdenakker G. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol 1992;41:29-34.
41. Kieseier BC, Kiefer R, Clements JM, Miller K, Wells GM, Schweitzer T, et al. Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain 1998;121:159-66.
42. Leppert D, Ford J, Stabler G, Grygar C, Lienert C, Huber S, et al. Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain 1998;121:2327-34.
43. Maeda A, Sobel RA. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol 1996;55:300-9.
44. Rosenberg GA, Dencoff JE, Correa N Jr, Reiners M, Ford CC. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology 1996;46:1626-32.
45. Leppert D, Hughes P, Huber S, Erne B, Grygar C, Said G, et al. Matrix metalloproteinase upregulation in chronic inflammatory demyelinating polyneuropathy and non-systemic vasculitic neuropathy. Neurology 1999;53:62-70.
46. Renaud S, Erne B, Fuhr P, Said G, Lacroix C, Steck AJ. Matrix metalloproteinases-9 and -2 in secondary vasculitic neuropathies. Acta Neuropathol (Berl) 2003;105:37-42.
47. Hughes PM, Wells GM, Clements JM, Gearing AJ, Redford EJ, Davies M, et al. Matrix metalloproteinase expression during experimental autoimmune neuritis. Brain 1998;121:481-94.
48. Leppert D, Waubant E, Galardy R, Bunnett NW, Hauser SL. T-cell gelatinases mediate basement membrane transmigration in vitro. J Immunol 1995;154:4379-89.
49. Romanic AM, Madri JA. The induction of 72-kD gelatinase in T cells upon adhesion to endothelial cells is VCAM-1 dependent. J Cell Biol 1994;125:1165-78.
50. Yong VW, Krekoski CA, Forsyth PA, Bell R, Edwards DR. Matrix metalloproteinases and diseases of the CNS. Trends Neurosci 1998;21:75-80.
51. Leppert D, Waubant E, Burk MR, Oksenberg JR, Hauser SL. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 1996;40:846-52.
52. Hadden RD, Sharrack B, Bensa S, Soudain SE, Hughes RA. Randomized trial of interferon beta-la in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1999;53:57-61.
53. Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 2000;19:6642-50.
54. Jann S, Bramerio MA, Beretta S, Koch S, Defanti CA, Toyka KV, et al. Diagnostic value of sural nerve matrix metalloproteinase-9 in diabetic patients with CIDP. Neurology 2003;61:1607-10.
55. Duggan DJ, Bittner M, Chen Y, Meltzer P, Trent JM. Expression profiling using cDNA microarrays. Nat Genet 1999;21:10-4.
56. Lockhart DJ, Dong H, Byrne MC, Follettie MT, Gallo MV, Chee MS, et al. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol 1996;14:1675-80.
57. McGall G, Labadie J, Brock P, Wallraff G, Nguyen T, Hinsberg W. Light-directed synthesis of high-density oligonucleotide arrays using semiconductor photoresists. Proc Natl Acad Sci U S A 1996;93:13555-60.
58. Renaud S, Hays A, Brannagan T, Sander H, Edgar M, Weimer L, et al. Gene expression profiling in CIDP. J Neuroimmunol 2005;159:203-14.
59. Miyazaki M, Ntambi JM. Role of stearoyl-coenzyme A desaturase in lipid metabolism. Prostaglandins Leukot Essent Fatty Acids 2003;68:113-21.
60. Zhang L, Ge L, Parimoo S, Stenn K, Prouty SM. Human stearoyl-CoA desaturase: alternative transcripts generated from a single gene by usage of tandem polyadenylation sites. Biochem J 1999;340:255-64.
61. Ntambi JM, Miyazaki M. Regulation of stearoyl-CoA desaturases and role in metabolism. Prog Lipid Res 2004;43:91-104.
62. Garbay B, Boiron-Sargueil F, Shy M, Chbihi T, Jiang H, Kamholz J, et al. Regulation of oleoyl-CoA synthesis in the peripheral nervous system: demonstration of a link with myelin synthesis. J Neurochem 1998;71:1719-26.
63. Utans U, Arceci RJ, Yamashita Y, Russell ME. Cloning and characterization of allograft inflammatory factor-1: a novel macrophage factor identified in rat cardiac allografts with chronic rejection. J Clin Invest 1995;95:2954-62.
64. Utans U, Quist WC, McManus BM, Wilson JE, Arceci RJ, Wallace AF, et al. Allograft inflammatory factor-1. A cytokine-responsive macrophage molecule expressed in transplanted human hearts. Transplantation 1996;61:1387-92.
65. Yang ZF, Ho DW, Lau CK, Lam CT, Lum CT, Poon RT, et al. Allograft inflammatory factor-1 (AIF-1) is crucial for the survival and pro-inflammatory activity of macrophages. Int Immunol 2005;17:1391-7.
66. Kelemen SE, Autieri MV. Expression of allograft inflammatory factor-1 in T lymphocytes: a role in T-lymphocyte activation and proliferative arteriopathies. Am J Pathol 2005;167:619-26.
67. Autieri MV, Carbone C, Mu A. Expression of allograft inflammatory factor-1 is a marker of activated human vascular smooth muscle cells and arterial injury, Arterioscler Thromb Vasc Biol 2000;20:1737-44.
68. Postler E, Rimner A, Beschorner R, Schluesener HJ, Meyermann R. Allograft-inflammatory-factor-1 is upregulated in microglial cells in human cerebral infarctions. J Neuroimmunol 2000;108:244-50.
69. Beschorner R, Engel S, Mittelbronn M, Adjodah D, Dietz K, Schluesener HJ, et al. Meyermann R. Differential regulation of the monocytic calcium-binding peptides macrophage-inhibiting factor related protein-8 (MRP8/S100A8) and allograft inflammatory factor-1 (AIF-1) following human traumatic brain injury. Acta Neuropathol (Berl) 2000;100:627-34.
70. Deininger MH, Seid K, Engel S, Meyermann R, Schluesener HJ. Allograft inflammatory factor-1 defines a distinct subset of infiltrating macrophages/microglial cells in rat and human gliomas. Acta Neuropathol (Berl) 2000;100:673-80.
71. Schluesener HJ, Seid K, Deininger M, Schwab J. Transient in vivo activation of rat brain macrophages/microglial cells and astrocytes by immunostimulatory multiple CpG oligonucleotides. J Neuroimmunol 2001;113:89-94.
72. Broglio L, Erne B, Tolnay M, Schaeren-Wiemers N, Fuhr P, Steck AJ, et al. Allograft inflammatory factor-1 in chronic inflammatory demyelinating polyneuropathy and vasculitic neuropathy. J Neurol 2006;253(Suppl 2):II/11.
73. Cao YQ, Mantyh PW, Carlson EJ, Gillespie AM, Epstein CJ, Basbaum AI. Primary afferent tachykinins are required to experience moderate to intense pain. Nature 1998;392:390-4.
74. Pennefather JN, Lecci A, Candenas ML, Patak E, Pinto FM, Maggi CA. Tachykinins and tachykinin receptors: a growing family. Life Sci 2004;74:1445-63.
75. McGillis JP, Mitsuhashi M, Payan DG. Immunomodulation by tachykinin neuropeptides. Ann NY Acad Sci 1990;594:85-94.
76. Lai JP, Douglas SD, Ho WZ. Human lymphocytes express substance P and its receptor. J Neuroimmunol 1998;86:80-6.
77. Ho WZ, Lai JP, Zhu XH, Uvaydova M, Douglas SD. Human monocytes and macrophages express substance P and neurokinin-1 receptor. J Immunol 1997;159:5654-60.
78. Ho WZ, Kaufman D, Uvaydova M, Douglas SD. Substance P augments interleukin-10 and tumor necrosis factor-alpha release by human cord blood monocytes and macrophages. J Neuroimmunol 1996;71:73-80.
79. Steck AJ, Murray N, Meier C, Page N, Perruisseau G. Demyelinating neuropathy and monoclonal IgM antibody to myelin-associated glycoprotein. Neurology 1983;33:19-23.
80. Kelly JJ, Adelman LS, Berkman E, Bhan I. Polyneuropathies associated with IgM monoclonal gammopathies. Arch Neurol 1988;45:1355-9.
81. Monaco S, Ferrari S, Bonetti B, Moretto G, Kirshfink M, Nardelli E, et al. Experimental induction of myelin changes by anti-MAG antibodies and terminal complement complex. J Neuropathol Exp Neurol 1995;54:96-104.
82. Mendell JR, Sahenk Z, Whitaker JN, Trapp BD, Yates AJ, Griggs RC, et al. Polyneuropathy and IgM monoclonal gammopathy: studies on the pathogenetic role of anti-myelin-associated glycoprotein antibody. Ann Neurol 1985;17:243-54.
83. Gabriel JM, Erne B, Miescher GC, Miller SL, Vital A, Vital C, et al. Selective loss of myelin-associated glycoprotein from myelin correlates with anti-MAG antibody titre in demyelinating paraproteinaemic polyneuropathy. Brain 1996;119:775-87.
84. Nobile-Orazio E, Manfredini E, Carpo M, Meucci N, Monaco S, Ferrari S, et al. Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann Neurol 1994;36:416-24.
85. Nobile-Orazio E, Baldini L, Barbieri S, Marmiroli P, Spagnol G, Francomano E, et al. Treatment of patients with neuropathy and anti-MAG IgM M-proteins. Ann Neurol 1988;24:93-7.
86. Ernerudh JH, Vrethem M, Andersen O, Lindberg C, Berlin G. Immunochemical and clinical effects of immunosuppressive treatment in monoclonal IgM neuropathy. J Neurol Neurosurg Psychiatry 1992;55:930-4.
87. Mariette X, Chastang C, Clavelou P, Louboutin JP, Leger JM, Brouet JC. A randomised clinical trial comparing interferon-alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM-associated Polyneuropathy Study Group. J Neurol Neurosurg Psychiatry 1997;63:28-34.
88. Mariette X, Brouet JC, Chevret S, Leger JM, Clavelou P, Pouget J, et al. A randomised double-blind trial versus placebo does not confirm the benefit of alpha-interferon in polyneuropathy associated with monoclonal IgM. J Neurol Neurosurg Psychiatry 2000;69:279-80.
89. Oksenhendler E, Chevret S, Leger JM, Louboutin JP, Bussel A, Brouet JC. Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. IgM-associated Polyneuropathy Study Group. J Neurol Neurosurg Psychiatry 1995;59:243-7.
90. Nobile-Orazio E, Meucci N, Baldini L, Di Troia A, Scarlato G. Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain 2000;123:710-7.
91. Onrust SV, Lamb HM, Balfour JA. Rituximab. Drugs 1999;58:79-88.
92. Latov N, Sherman WH. Therapy of neuropathy associated with anti-MAG IgM monoclonal gammopathy with rituxan. Neurology 1999;52:A551.
93. Levine TD, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab. Neurology 1999;52:1701-4.
94. Renaud S, Gregor M, Fuhr P, Lorenz D, Deuschl G, Gratwohl A. Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve 2003;27:611-5.
95. Renaud S, Fuhr P, Gregor M, Schweikert K, Lorenz D, Daniels C, et al. High Dose Rituximab and Anti-MAG-Associated Polyneuropathy. Neurology 2006;66:742-4.
96. Pestronk A, Florence J, Miller T, Choksi R, Al-Lozi MT, Levine TD. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 2003;74:485-9.